Researchers at the University of Surrey have announced the development of a new anti-HIV drug, MK-8527. The findings were published in the British Journal of Pharmacology. Scientists hope this drug can be used for infection prevention, offering protection against the virus for an entire month with just a single pill.
MK-8527 belongs to the class of reverse transcriptase inhibitors. Inside cells, it transforms into an active form, blocking a crucial step in the virus`s replication process. Laboratory tests have shown that the substance effectively suppresses HIV growth even at minimal doses.
In experiments on rats and macaques, the drug demonstrated good absorption and remained in immune cells for approximately 48 hours, indicating a prolonged effect. It is anticipated that in humans, it could be administered just once a month, as opposed to daily pill regimens.
Furthermore, MK-8527 did not exhibit significant side effects or interfere with the function of other enzymes. Clinical trials are now underway to confirm the safety and efficacy of this new agent. If successful, the drug could become a convenient alternative to daily therapy and offer help to millions of people at risk of HIV infection.
Previously, there were also reports about the development of gene therapy capable of protecting newborns from HIV with a single injection.
